Latest Trials Latest NewsFAQ

WASHINGTON UNIVERSITY SCHOOL OF MEDICINE

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1891-01-01

Employees: 10K

Market Cap: -

Website: http://www.medschool.wustl.edu

Clinical Trials

Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Extensive-stage Small Cell Lung Cancer

Interventions: Biological: Neoantigen DNA vaccine
Drug: Durvalumab
Device: TDS-IM v2.0 Device
Procedure: Peripheral blood draws

First Posted Date: 2020-05-21

Last Posted Date: 2024-04-26

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 20

Registration Number: NCT04397003

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

De-escalated Conformal Radiation Expedited Sequentially With Chemotherapy for Endometrial Cancer

Phase 1

Recruiting

Conditions: Endometrial Cancer

Interventions: Radiation: Intensity modulated radiation therapy

First Posted Date: 2020-05-13

Last Posted Date: 2023-10-26

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 25

Registration Number: NCT04386993

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Palliative Expeditiously Adaptive Quad Shot Radiation Therapy (PEAQ-RT)

Not Applicable

Completed

Conditions: Head and Neck Cancer

Interventions: Device: Ring gantry kV-CBCT combined with linear accelerator (Halcyon)
Radiation: Quad shot radiation

First Posted Date: 2020-05-07

Last Posted Date: 2023-12-08

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 10

Registration Number: NCT04379505

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Duvelisib to Combat COVID-19

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: Duvelisib
Drug: Placebo
Procedure: Peripheral blood draw

First Posted Date: 2020-05-04

Last Posted Date: 2023-03-06

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 28

Registration Number: NCT04372602

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Extensive-stage Small Cell Lung Cancer

Interventions: Drug: Vorolanib
Drug: Atezolizumab

First Posted Date: 2020-05-04

Last Posted Date: 2024-05-16

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 11

Registration Number: NCT04373369

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

De-Implementation of Unnecessary Surgical Antibiotic Prophylaxis in Children

Not Applicable

Completed

Conditions: Surgical Site Infection

Interventions: Other: Order set review and modification
Behavioral: Order set review and modification with facilitation

First Posted Date: 2020-04-28

Last Posted Date: 2024-12-10

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 39363

Registration Number: NCT04366440

Locations: 🇺🇸
Johns Hopkins University School of Medicine / Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States
🇺🇸
Harvard Medical School / Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
University of Michigan / CS Mott Children's Hospital, Ann Arbor, Michigan, United States

and more 7 locations

Systemic Absorption of Lidocaine After Hematoma Block

Phase 4

Withdrawn

Conditions: Lidocaine
Hematoma
Pediatrics
Radius Fracture Distal

Interventions: Drug: Lidocaine 1% Injectable Solution

First Posted Date: 2020-04-24

Last Posted Date: 2023-12-18

Lead Sponsor: Washington University School of Medicine

Registration Number: NCT04359017

Locations: 🇺🇸
Saint Louis Children's Hospital, Saint Louis, Missouri, United States

Evaluation of Antibody Tests for COVID-19

Completed

Conditions: Coronavirus
COVID

Interventions: Diagnostic Test: Diagnostic test

First Posted Date: 2020-04-24

Last Posted Date: 2024-06-04

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 461

Registration Number: NCT04360954

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Ruxolitinib to Combat COVID-19

Phase 2

Withdrawn

Conditions: COVID-19

Interventions: Drug: Ruxolitinib
Procedure: Peripheral blood draw

First Posted Date: 2020-04-21

Last Posted Date: 2020-05-21

Lead Sponsor: Washington University School of Medicine

Registration Number: NCT04354714

Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML

Phase 2

Withdrawn

Conditions: Refractory Acute Myeloid Leukemia
Relapsed Acute Myeloid Leukemia

Interventions: Biological: Cytokine induced memory-like NK cells
Procedure: Leukapheresis
Drug: Fludarabine
Drug: Ara-C
Drug: G-CSF
Drug: Interleukin-2

First Posted Date: 2020-04-21

Last Posted Date: 2023-04-04

Lead Sponsor: Washington University School of Medicine

Registration Number: NCT04354025

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy